Trial reportAnnals of surgery1999
Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment.
Trial report in Annals of surgery, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- Quantification of an Exercise Rehabilitation Program for Severely Burned Children: The Standard of Care at Shriners Hospitals for Children®-Galveston.Journal of burn care & research : official publication of the American Burn Association · 2018Guideline
- Reduced Postburn Hypertrophic Scarring and Improved Physical Recovery With Yearlong Administration of Oxandrolone and Propranolol.Annals of surgery · 2018Trial
- Amino acid infusion fails to stimulate skeletal muscle protein synthesis up to 1 year after injury in children with severe burns.The journal of trauma and acute care surgery · 2013Trial
- Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety.Pediatric research · 2013Trial
- Trial
- A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants.Pediatric research · 2009Trial
- Pathophysiologic response to severe burn injury.Annals of surgery · 2008Trial
- Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment.Annals of surgery · 2005Trial
- Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.Hormone research · 2005Trial
- Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned.Annals of surgery · 2003Trial
- Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Serious Infections in Burn-Injured Adults: A Retrospective Single-Center Study from 1997 to 2023.Journal of burn care & research : official publication of the American Burn Association · 2026Article
- Endocrine disruptions in thermal injuries: exploring immune system interactions.Physiological reviews · 2026Review
- Hypermetabolism and Lipid Alterations Postburn: A Cardiovascular Perspective.Cardiovascular therapeutics · 2026Review
- Metabolic and Hormonal Changes in Pediatric Burn Patients: Mechanisms, Evidence, and Care Strategies.European burn journal · 2025Review
- Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).Journal of inflammation research · 2025Review
- Update on Hypermetabolism in Pediatric Burn Patients.Seminars in plastic surgery · 2024Review
- Nutrition in Pediatric Burns.Seminars in plastic surgery · 2024Review
- Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities.British journal of anaesthesia · 2024Review
- Metabolic response to burn injury: a comprehensive bibliometric study.Frontiers in medicine · 2024Article
- Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine the effects of recombinant human insulin-like growth factor-1 (IGF-1) complexed with its principal binding protein, IGFBP-3, on skeletal muscle metabolism in severely burned children. SUMMARY BACKGROUND DATA: Severe burns are associated with a persistent hypermetabolic response characterized by hyperdynamic circulation and severe muscle catabolism and wasting. Previous studies showed that nutritional support and pharmacologic intervention with anabolic agents such as growth hormone and insulin abrogated muscle wasting and improved net protein synthesis in the severely burned. The use of these agents, however, has several adverse side effects. A new combination of IGF-1 and IGFBP-3 is now available for clinical study.
methodsTwenty-nine severely burned children were prospectively studied before and after treatment with 0.5, 1, 2, or 4 mg/kg/day IGF-1/IGFBP-3 to determine net balance of protein across the leg, muscle protein fractional synthetic rates, and glucose metabolism. Another group was studied in a similar fashion without IGF-1/IGFBP-3 treatment as time controls.
resultsSeventeen of 29 children were catabolic before starting treatment. The infusion of 1.0 mg/kg/day IGF-1/IGFBP-3 increased serum IGF-1, which did not further increase with 2.0 and 4.0 mg/kg/day. IGF-1/IGFBP-3 treatment at 1 to 4 mg/ kg/day improved net protein balance and increased muscle protein fractional synthetic rates. This effect was more pronounced in catabolic children. IGF-1/IGFBP-3 did not affect glucose uptake across the leg or change substrate utilization.
conclusionsIGF-1/IGFBP-3 at doses of 1 to 4 mg/kg/day attenuates catabolism in catabolic burned children with negligible clinical side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.